ProQR Therapeutics Q1 2024 GAAP EPS €(0.03) Beats €(0.11) Estimate, Sales €6.305M Miss €11.460M Estimate, €96.2M Cash Position As Of End Of Q2 Providing Runway Into Mid-2026
Portfolio Pulse from Benzinga Newsdesk
ProQR Therapeutics reported a Q1 2024 GAAP EPS of €(0.03), beating the estimate of €(0.11). However, sales of €6.305M missed the estimate of €11.460M. The company has a cash position of €96.2M as of the end of Q2, providing a runway into mid-2026.
August 08, 2024 | 12:22 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
ProQR Therapeutics reported better-than-expected Q1 2024 GAAP EPS but missed sales estimates. The company has a strong cash position, providing financial stability until mid-2026.
The better-than-expected EPS is a positive sign, but the missed sales estimate is a concern. The strong cash position provides financial stability, balancing the overall impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100